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ABSTRACT 
Sarcoidosis is a systemic disease of unknown etiology characterized by the formation 
of non-necrotizing granulomas in the affected organs.  Engagement of the lungs and/or 
thoracic lymph nodes (LN) are found in more than 90 % of all cases, but almost any 
organ such as the eyes, skin, heart and nervous system can be involved. Genetic factors 
influence the risk for disease as well as the clinical picture seen in sarcoidosis and 
especially the genes localized to the human leukocyte antigen (HLA) region on 
chromosome six are believed to be of importance. For example, the HLA-DRB1*0301 
allele is found to be strongly associated with Löfgren’s syndrome (LS). Characteristic 
for LS is an acute onset usually with fever, bilateral ankle arthritis and/or erythema 
nodosum and bilateral hilar lymphadenopathy with in some cases parenchymal 
infiltrates. The HLA-DRB1*0301 allele is also associated with an accumulation of T 
cells expressing the T cell receptor variable gene segment AV2S3 in bronchoalveolar 
lavage fluid (BALF) of sarcoidosis patients. 
 
The aim of this thesis has been to identify risk factors for different clinical 
manifestations in sarcoidosis as well as markers of importance for the inflammatory 
cell response seen in sarcoidosis. 
   
The results show that HLA-DRB1*04 positive sarcoidosis patients had an increased 
risk for the three organ engagements associated with Heerfordt´s syndrome. Heerfordt´s 
syndrome is a phenotype of sarcoidosis that in its complete form consists of uveitis, 
parotid and/or salivary gland enlargement and cranial nerve palsy.  
 
In comparison to BALF where a high CD4/CD8-ratio is strongly associated with 
sarcoidosis, the CD4/CD8-ratio in the affected LNs of sarcoidosis patients had no 
diagnostic value. Further, in HLA-DRB1*03 positive patients the associated 
accumulation of AV2S3+ T cells was strictly compartmentalized in BALF. This 
finding indicates an airborne antigen as the triggering factor in sarcoidosis. 
 
The risk for cardiac sarcoidosis (CS) was significantly higher in patients with an 
abnormal electrocardiography (ECG) compared to those with a normal ECG. The risk 
for CS was highest in patients who had a pathologic ECG in combination with cardiac 
related symptoms. Further, non-LS was associated with an increased risk for CS. 
 
In LS patients was the absence of HLA-DRB1*03 a risk factor for extra-pulmonary 
manifestations (erythema nodosum and ankle arthritis excluded). Another risk marker 
in all patients was HLA-DRB1*04/*15 where half of the patients had extra-pulmonary 
manifestations. 
 
In conclusion, the HLA-DRB1*04 allele is associated with an increased risk for 
involvement of the eyes, parotid and/or salivary glands and cranial nerves in 
sarcoidosis patients. Moreover, an increased CD4/CD8-ratio in enlarged LNs is not 
diagnostic for sarcoidosis in comparison to BALF where a high ratio is strongly 
associated with sarcoidosis. Further, a pathologic ECG is a risk marker for CS in 
sarcoidosis patients. Finally, not only the single HLA-DRB1 alleles are of importance 
for the risk of extra-pulmonary manifestations in sarcoidosis, but also the allele 
combinations and where especially the combination HLA-DRB1*04/*15 calls for an 
increased awareness and a more intensive follow-up. 
 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Sarkoidos är en inflammatorisk sjukdom som vanligtvis drabbar unga vuxna i åldrarna 
20-40 år. Orsaken till sjukdomen är okänd. I Sverige insjuknar årligen ungefär 1500-
2000 personer i sarkoidos. Lungförändringar ses hos de allra flesta med sarkoidos, men 
inte bara lungorna drabbas utan även andra organ kan engageras. Detta kan yttra sig i 
form av ögoninflammationer, svullna lymfkörtlar, nytillkomna hudförändringar 
och/eller oregelbunden hjärtrytm. I de angripna organen ses de för sjukdomen 
karakteristiska granulomen. Granulomen är ett sätt för kroppen att avskärma icke-
eliminerbara antigen. Sarkoidos läker hos en del ut spontant inom två års tid medan 
andra får ett sjukdomsförlopp av mer kronisk karaktär. Vid svårare former av sarkoidos 
brukar behandling med kortikosteroider prövas. Behandlingen har i regel en 
symtomlindrande effekt på kort sikt, men det saknas vetenskapliga bevis för att 
behandling på lång sikt påverkar sjukdomsutvecklingen. 
 
Vid sarkoidos leder inflammationen i lungorna till att vita blodkroppar ansamlas, vilka 
främst utgörs av CD4 positiva T-celler men också till viss del av CD8 positiva T-celler. 
T-cellerna aktiveras i lungornas lymfknutor via de antigenpresenterande cellerna. De 
antigenpresenterande cellerna visar upp delar av potentiellt skadliga partiklar som de 
har tagit upp för T-celler i form a små proteinfragment, men även kroppsegna ämnen 
visas upp. Normalt ska dock endast de skadliga partiklarna leda till aktivering av 
immunförsvaret. Presentationen av olika proteinfragment sker via de 
antigenpresenterande cellernas s k human leukocyte antigen (HLA)-molekyler vilka är 
receptorer som sitter fästa i cellmembranet. T-cellerna har motsvarande receptorer, 
vilka kallas för T-cellsreceptorer och finns i miljontals olika varianter. Bara de T-celler 
som har den rätta passformen på sina receptorer kan binda ett specifikt komplex av 
HLA-molekyl med bundet antigen.  
 
Generna som styr HLA-molekylernas utseende finns i olika varianter och kallas för 
HLA-alleler. Vid sarkoidos, men även vid många andra inflammatoriska sjukdomar 
finns det kopplingar mellan HLA-alleler och risk att utveckla sjukdom. Vid sarkoidos 
är exempelvis HLA-genen HLA-DRB1*03 klart överrepresenterad hos patienter med 
Löfgrens syndrom. Löfgrens syndrom är en form av sarkoidos som karakteriseras av ett 
akut insjuknande med feber, smärta och svullnad utav fotleder och/eller röda ömmande 
utslag på underbenen, så kallad knölros, och förstorade lymfkörtlar centralt kring 
luftrören samt ibland även på lungröntgen synliga infiltrat. HLA-DRB1*03 hos 
patienter med sarkoidos är även kopplat till en ansamling av av CD4 positiva T-celler i 
lungorna vilka uttrycker T-cellsreceptorer med ett segment som kallas AV2S3. 
 
Syftet med studierna i denna avhandling har varit att undersöka samband mellan olika 
faktorer bl a HLA-alleler och risken att drabbas av olika organmanifestationer. Ett 
delmål har också varit att öka förstålsen kring de inflammatoriska cellerna som 
återfinns i lungorna och betydelsen av olika markörer för det inflammatoriska svaret. 
 
Resultaten visar att HLA-DRB1*04 positiva sarkoidospatienter hade en ökad risk att 
drabbas av någon av de tre organmanifestationerna som ses vid Heerfordt´s syndrom. 
   
Heerfordt´s syndrom är en typ av sarkoidos som i sin kompletta form består av 
ögoninflammation, svullnad av spottkörtlar och engagemang utav någon av 
kranialnerverna, vanligast är förlamning av ena ansiktsnerven.  
 
Till skillnad från en förhöjd CD4/CD8-kvot (antalet CD4+ T-celler/CD8 + T-celler) i 
lungsköljvätska, vilken är starkt kopplad till sarkoidos, visar resultaten att en förhöjd 
CD4/CD8-kvot i de förstorade lymfkörtlarna i lungorna var ett ospecifikt fynd vid 
sarkoidos. De specifika lymfocyter (så kallade AV2S3+ T-celler) som ansamlas i 
lungorna hos HLA-DRB1*03 positiva patienter, återfanns inte i samma grad i de 
förstorade lymfkörtlarna hos dessa individer. T-celler från blod och lymfkörtlar var 
dessutom inte heller i lika hög grad differentierade jämfört med de i lungsköljvätska. 
Resultaten visar således att inflammationen vid sarkoidos främst är lokaliserad till de 
små luftvägarna.  
 
Vidare var risken för hjärtengagemang hos patienter med sarkoidos starkt associerad 
med ett avvikande elektorkardiogram (EKG). Allra störst var risken hos de patienter 
som hade EKG-förändringar ihop med symtom i form av hjärtklappning eller 
svimningskänsla/svimning. En ytterligare riskfaktorer för hjärtsarkoidos var icke 
Löfgrens syndrom. Patienter med ett normalt EKG och utan symtom på hjärtbesvär vid 
insjuknandet hade således en mycket låg risk att senare utveckla hjärtsarkoidos.  
 
Vi fann även att avsaknaden av HLA-DRB1*03 var en riskfaktor för engagemang av 
ytterligare organ utöver lungorna hos patienter med Löfgrens syndrom (symtom ifrån 
fotleder samt knölros borträknade). En annan riskfaktor för engagemang av andra organ 
än enbart lungorna var HLA-DRB1*04/*15 där detta sågs hos hälften av alla 
patienterna med sarkoidos 
 
Sammanfattningsvis var förekomsten av den genvariant som kallas HLA-DRB1*04 hos 
patienter med sarkoidos kopplad till en ökad risk för engagemang utav ögon, 
spottkörtlar och hjärnnerver. Vidare så var en förhöjd CD4/CD8-kvot i de förstorade 
lymfknutorna i lungorna ett ospecifikt fynd i motsats till en förhöjd CD4/CD8-kvot i 
lungsköljvätska, vilken är starkt associerad med sarkoidos. Baserat på resultaten i 
denna avhandling bör alla sarkoidospatienter med ett avvikande EKG utredas för 
hjärtsarkoidos. Slutligen så visar fynden i denna avhandling att arvsmassan i form av 
HLA-DRB1 alleler har stor betydelse för risken att drabbas av olika organengagemang 
vid sarkoidos. Således kan HLA-typning utgöra ett bra komplement för att identifiera 
sarkoidospatienter med hög risk att drabbas av ytterligare organengagemang utöver 
lungorna. 
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  1 
GENERAL INTRODUCTION 
 
Sarcoidosis was first described in 1899 as a skin disease by the Norwegian 
dermatologist Caesar Boeck. He thought the typical foci of epitheloid cells and giant 
cells resembled sarcoma and called the condition “multiple benign sarcoid of the skin”.  
Later, in 1909 another manifestation of sarcoidosis was described by the Danish 
ophthalmologist Christian Heerfordt who had observed three patients with uveitis, 
parotid swelling and cranial nerve palsy. The triad of symptoms was named Heerfordt´s 
syndrome, but was first in 1937 classified as a distinct manifestation of sarcoidosis by 
the Swedish physician Jan Waldenström. Another form of sarcoidosis was described 
in 1952 by the Swedish physician Sven Löfgren, which he called “the bilateral hilar 
lymphoma syndrome”, later named Löfgren´s syndrome. Characteristic for this 
syndrome is illness, high fever, ankle arthritis and / or erythema nodosum and bilateral 
enlarged medistinal lymph nodes with or without bilateral pulmonary infiltrates.  
 
Almost any organ can be affected in sarcoidosis, although the lungs are involved in 
more than 90% of all cases. What causes the disease is, however, still unknown. 
Sarcoidosis is found throughout the world, but the clinical presentation and frequency 
differ. The disease outcome in sarcoidosis varies from spontaneous resolution to 
progressive disease with development of pulmonary fibrosis. 
 
The overall aim of this thesis has been to improve our understanding on why the 
clinical picture in sarcoidosis is so highly variable and to identify risk factors which can 
be used in the clinic for early identification of high risk patients with regard to extra-
pulmonary manifestations. 
 
Hopefully, the results from this thesis will be applicable to the everyday clinical 
practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
1 THE IMMUNE SYSTEM 
 
The immune system is divided into the innate and adaptive part. The role of the innate 
immune system is to provide a first line of defense against pathogens. If a pathogen 
breaks through the barriers of the innate immune system, the adaptive immune system 
will take over. However, the defense mechanisms of the adaptive immune system take 
days to develop and during this period the innate immune system plays a critical role 
(1).  
 
 
1.1 INNATE IMMUNITY 
The principal defense components of the innate immune system are several and where 
the epithelial cells serve as a structural barrier, cytokines as directing signal proteins, 
macrophages and dendritic cells (DC) are important for activation of the adaptive 
immune system, neutrophils together with the macrophages are major phagocytes and 
recruit other cells to the site of inflammation. There are also natural killer (NK) cells 
capable to directly kill infected cells. Finally, the proteins of the complement system 
can cause damage to the membrane of pathogens or coat them so that they are more 
easily phagocytized (2).   
 
 
1.1.1 Inflammatory mediators 
Cytokines are signal proteins involved in the communication between cells in both the 
innate and adaptive immune system. Some cytokines promote inflammation (pro-
inflammatory cytokines) and others suppress inflammation (anti-inflammatory 
cytokines). Cytokines also influence the differentiation of cells, for example T cells, 
into either T helper (Th)1 or Th2 cells (2, 3). Chemokines are another group of signal 
proteins which have chemotactic properties. They are important for recruitment of 
inflammatory cells from the circulation into infected tissues (4). 
 
 
1.1.2 Macrophages 
Macrophages originate from monocytes and differentiate into macrophages when they 
migrate from the blood to the lungs (5). The macrophages are phagocytes responsible 
for clearance of pathogens and have housekeeping functions.  They can either be 
activated through the classic pathway or be alternatively activated macrophages 
(AAMs) (6). The classic pathway is induced by the Th1 cytokine interferon (IFN)-γ (7). 
Macrophages activated via the classic pathway produce interleukin (IL)-1, IL-6, and 
tumor necrosis factor (TNF)-α, all important cytokines for the clearance of intracellular 
and bacterial pathogens. The differentiation of macrophages into AAMs is stimulated 
by the Th2 cytokines IL-4 and IL-13. The role of AAMs is not fully clear, but they are 
thought to be involved in the eradication of extracellular parasites and in several 
chronic airway diseases (8, 9). 
 
 
  3 
1.1.3 Dendritic cells 
DCs link the innate immune system with the adaptive immune system. For the 
recognition of pathogens the DCs have receptors termed pattern recognition receptors 
(PRR). After activation, the DC travels to a neighboring lymph node (LN) and there 
present the antigen it has encountered to T cells (10, 11).  
 
 
1.1.4 Neutrophils 
Neutrophils are normally found in the blood stream and are one of the first cells that 
migrate to the site of inflammation. They are phagocytes and recognize antigens that 
for example are opsonized (covered for recognition) with antibodies (12). Neutrophils 
will eliminate microbes by first phagocytize and then enzymatically digest them (13). 
They also produce cytokines that are important for the inflammatory answer (14). 
 
 
1.1.5 Natural killer cells 
NK cells are lymphocytes that are able to directly kill target cells and are important for 
the defense against viral infections. NK cells are activated by infected cells that express 
ligands for the NK cell´s activating receptors. There are also other receptors with 
inhibitory functions on NK cells, identifying the major histocompatibility complex 
(MHC) class I molecules found on all healthy cells. A loss of MHC class I receptors 
due to infection or transformation into cancer cells will lead to activation of NK cells 
(15-17). There are also cytokines that enhance the activity of NK cell such as the virus-
induced type 1 interferons, IFN-α and β (18, 19). NK cells produce cytokines 
themselves such as IFN-γ and TNF-α (20). 
 
 
1.1.6 Innate immune recognition 
PRRs of the cells of the innate immune system recognize pathogens through molecules 
in the bacterial cell membrane. The structures that the PRRs bind to are termed 
pathogen-associated molecular patterns (PAMP) (13, 21, 22). Among the PRRs, the 
most well-known is the toll-like receptors (TLR) (23, 24). The TLR was first 
discovered in fruit-flies and later on in humans (25-27). Mutations in the TLR genes 
have been associated with severe bacterial infections (28, 29). For the discovery of the 
critical role of the TLRs, Jules Hoffman and Bruce Beutler were rewarded with the 
Nobel Prize in 2011.  
 
 
1.2    ADAPTIVE IMMUNITY 
Characteristics for the adaptive immune system are specificity, memory and diversity. 
The main cells of the adaptive immune system are the lymphocytes which are divided 
into T cells and B cells. Example of T cells are the Th1 cells which enhance 
macrophages ability to phagocyte and kill pathogens and the Th2 cells important for the 
activation of B cells, cytotoxic T lymphocytes (CTL) which kill cells infected with 
viruses or intracellular bacteria, T regulatory cells (Treg) that suppress other T cells 
from reacting against self-antigens and Th17 cells which are believed to be involved in 
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the defense against bacterial infections and may be of importance for developing 
autoimmune diseases. The B cells are able to transform into antibody producing plasma 
cells which neutralize bacterial toxins, activate the complement system and opsonize 
bacteria and thereby facilitate the phagocytosis of them (2).  
 
 
1.2.1 Antigen presentation  
For the activation of T cells the antigen presentation is important. Involved in this 
process are macrophages, DCs and B cells, termed antigen presenting cells (APC). T 
cells not yet activated by APC are named naïve T cells. Naïve T cells circulate 
continuously between the blood and lymph nodes (LN).  When a naïve T cell meet 
within a LN an APC which presents the right antigen, the naïve T cell will become 
activated (30, 31). APCs have specific receptors on the cell surface used for antigen 
presentation termed major histocompatibility complex (MHC), which in humans is 
named human leukocyte antigen (HLA) receptor (Figure 1) (32). T cells have receptors 
named T cell receptors (TCR) by which they bind to the MHC receptor. TCRs are only 
able to bind to a complex of an antigen bound to an APCs´ MHC molecule if it has the 
right pass form (33-37). For this discovery of  MHC restricted antigen recognition, Rolf 
Zinkernagel and Peter Doherty were rewarded with the Nobel prize in 1996  (38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Antigen presentation. 
 
The interaction between  T cells and APCs are enhanced by specific co-receptors 
named cluster of differentiation (CD) 4 (found on CD4+ T cells) and CD8 (found on 
CD8+ T cells) (39). The CD4 co-receptor only binds to MHC class II molecules and 
CD8 to MHC class I molecules.  After activation the naïve T cell will proliferate and all 
T cells produced will have the same specificity of their TCR as the initially stimulated 
T cell had. These new T cells are named effector T cells since they produce molecules 
able to eliminate antigens. The effector T cells will eventually leave the LNs and 
accumulate at site of inflammation, stimulated by the antigen that the naïve T cell 
initially was presented to (40). Still, after several years there are specific T cells able to 
recall antigens they once have been stimulated by. These T cells are named memory T 
cells and there are two different types: effector memory T cells and central memory T 
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cells. Effector memory T cells react immediately upon antigenic stimulation, but lack 
LN homing receptors.  The central memory T cells on the other hand have LN homing 
receptors and do therefore confer a more superior protection compared to the effector 
memory T cells (41). 
 
 
1.2.2 Human leukocyte antigen class I and II 
The HLA-molecules are coded by genes that belongs to either HLA class I or II (42). 
The third class, HLA class III, encodes for proteins involved in the complement system 
and cytokines such as TNF. The genes of the HLA region are localized on chromosome 
six (43). HLA class I genes encodes for HLA class I molecules found on the cell-
surface of all cells. HLA class I molecules are used for the presentation of intracellular 
peptides to CD8+ T cells. HLA class II is found on the cell-surface of APCs which use 
the receptor to present peptides they have taken up and degraded to T cells and B cells 
(44).  
 
The HLA class I and II molecules have one α- and β-chain (45). There are three 
classical variants of HLA class I: HLA-A, -B and –C. The genes of HLA class II are 
named HLA-DR, -DP and –DQ (Figure 2) (46, 47). There are separate genes encoding 
the α- and β-chains. Variants of these genes ("alleles") code for distinct HLA molecules 
and the HLA-DRB1 gene includes variants termed e.g. HLA-DRB1*01,*03,*04,*07, 
*08, *09, *10, *11, *12,*13,*14,*15,*16. Since there is one allele inherited from each 
parent, a combination may for example be HLA-DRB1*01/*03 (48). Since the HLA 
class I and II alleles encode for receptors involved in the antigen presentation, the high 
diversity minimizes the risk for a pathogen to escape detection (49). The variation of 
alleles have developed during the evolution and as a result there are differences 
between ethnic groups (50).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HLA alleles. Adopted  from Hurley et al (51). 
 
Several autoimmune diseases are associated with the HLA alleles (52, 53). One of the 
first described is ankylosing spondylitis strongly linked to HLA-B27 (54). Another 
disease is diabetes type I where there is an increased risk in individuals who carry 
HLA-DRB1*03 or *04, and highest is the risk in those who carry both the alleles (55). 
HLA-DRB1*04 is also in the Northern Europe associated with rheumatoid arthritis 
(56). One theory proposed about how the HLA-alleles contribute to the autoimmunity 
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is that individuals with an autoimmune disease-associated MHC phenotype will allow 
potentially self-reactive T cell clones during the process of positive and negative 
selection in the thymus. The varying penetrance of autoimmune diseases in individuals 
with a MHC-associated phenotype would then depend on the likelihood that T cells 
with the correct set of V(variable) - J (joining) α and V- D (diversity) - J β heterodimers  
will be formed (see next chapter) (57). 
 
 
1.2.3 The T cell receptor 
The TCR consists of one α- and β-chain and each chain has a constant (C) and a V 
region. The V region is responsible for the antigen recognition (58). The V region of 
the α-chain consists of  randomly combined V- and J-  segments and the same region of 
the β-chain of  V-, D and J segments (59). In the V region of each α-chain and β-chain 
there are three highly diverse loops termed complementary determining regions (CDR).  
Out of these three, CDR3 is the most variable and play a major role in the interaction 
with antigen peptides presented on MHC molecules (60). The TCR´s structure 
resembles the antibody’s and there are important structural sites on antibodies also 
found on TCRs (61). Similar to antibodies the antigen binding site of the TCR is 
created by gene rearrangements, which generates an immense diversity. TCRs are 
therefore able to interact with virtually any antigen (62, 63). During this recombination 
process, there is a random addition or removal of nucleotides at the junctions between 
the segments, in order to increase diversity of the TCR. The exon is then spliced 
together with the C region (59).    
 
In contact with an antigen, only a small fraction of T cells will proliferate and 
differentiate into effector cells (64). Expansion of T cells with a certain TCR able to 
identify specific antigens have been described in both infectious (65, 66) and 
inflammatory diseases (67-70). Since the V region is important for the antigenic 
recognition, a mutation in this region may lead to an altered antigen specificity of the 
TCR (71). In addition to the αβ TCR there is also a few percentages of TCRs built up 
by γ and δ chains. The function of the γδ TCR is not yet known (72, 73).  
 
During the T cell development all T cells go through positive and negative selection 
processes (74-76). During this procedure it is also decided if a T cell will be CD4+ or 
CD8+. Initially all T cells are double positive. Later, the T cells that bind to MHC class 
I will lose expression of co-receptor CD4 and be only CD8+, and those who bind to 
MHC class II will lose expression of CD8 and be only CD4+ (77). Since some self-
reactive T cells will escape the system of negative selection in the thymus, there are 
several back-up systems in the periphery to protect the body against autoimmune 
reactions. These defense mechanisms include deletions of self-reactive T cells and 
unresponsiveness if there is no co-stimulation (anergy) (78, 79) and suppression via 
Tregs (80). 
 
There are several mechanisms proposed to explain how self-reactive T cells can be 
activated despite the protective systems in the periphery. One of them is that cytokines 
released by APCs during an infection may lead to a more efficient antigen presentation 
of self-antigens to self-reactive T cells (81). Another is molecular mimicry, i.e. that a 
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pathogen mimics a self-antigen and which leads to a cross-reaction where the immune 
response against a viral or bacterial infection is re-directed to self-cells and tissues (82, 
83). Furthermore, superantigens produced by viruses or bacteria (for example 
staphylococcal enterotoxins) cause non-specific T cell activations. Superantigens are 
able to bind to MHC class II molecules and the complexes that are formed can interact 
with certain T cells by binding to their TCRs´ Vβ element and thereby stimulate these T 
cells, irrespective of their fine-specificity. T cell populations stimulated by 
superantigens are therefore polyclonal, but have certain TCR Vβ gene expressions in 
common (84-87). Moreover, a viral infection may lead to exposure of cellular proteins 
normally shielded from the immune system by making them aberrantly expressed (88-
91). 
 
 
1.2.4 Cell surface molecules 
The nomenclature CD is used for identification of cell surface molecules found on 
leukocytes such as adhesions molecules or receptors important for cell signaling. They 
are identified by panels of monoclonal antibodies used to investigate a particular cell 
type or stage of cell differentiation, for example do Th cells express the co-receptor 
CD4 and cytotoxic T cells CD8. T helper cells are therefore said to be CD4+ and 
cytotoxic T cells to be CD8+.  Both CD4+ and CD8+ T cells are said to be CD3+ since 
they express another marker, CD3, which consists of a complex of three proteins 
closely attached to the TCR (2). CD69 and CD27 are examples of markers of activation 
and differentiation. CD69 is expressed on very early activated T cells, already 1-2 
hours after stimulation, and persists for at least three days (92), while CD27 is 
expressed by naïve T cells and is up-regulated during T cell activation, but gradually 
down-regulated as the T-cells differentiate (93). 
 
 
1.2.5 T helper cell 1 and 2 
Th cells are divided into several subgroups. This chapter will focus on the two first 
discovered types, Th1 and Th2. The Th1 cells are mainly responsible for the defense 
against intracellular pathogens by activation of macrophages, enhancing their ability to 
phagocyte and kill pathogens. The Th2 cells are important for the extra-cellular 
immunity and humoral response, i.e. clearance of extracellular pathogens, parasites and 
toxins and for the proliferation and differentiation of B cells (94, 95). The 
differentiation of T cells into Th1 or Th2 cells is influenced by cytokines and the two 
subsets themselves do also produce cytokines (Figure 3) (96). For example IL-12 
produced by APCs promotes naïve T cells to differentiate into Th1 cells (97-99) and 
IL-4 induces Th2 differentiation (100). Typical cytokines produced by Th1 cells are IL-
2, TNF and INF-γ and by Th2 cells IL-4, IL-5, IL- 10 and IL-13.  Th1 and Th2 cells 
also regulate each other so that the Th1 cytokines inhibit the proliferation of Th2 cells 
and vice versa (101). 
 
 
1.2.6 T helper 17 cells 
Previously it was believed that the Th cells consisted only of Th1 or Th2 cells. In 
allergy research it was much discussed that an imbalance of these two could cause 
allergic diseases. The discovery of a third subgroup named Th17 has therefore filled an 
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essential gap in the understanding of inflammatory processes. The hallmark cytokine of 
Th17 is IL-17 (IL-17A) which has pro-inflammatory properties and stimulates 
production of anti-microbial peptides, cytokines, chemokines and growth factors 
leading to recruitment of neutrophils and inflammation (102). IL-17 binds to IL-17 
receptors found on fibroblasts, epithelial cells and keratinocytes (2, 103). Th17 cells 
also produce IL-17F, IL-6, IL-21, IL22 and TNF-α (104). Th17 cells are mainly found 
close to epithelial cells and protect against extracellular bacteria and fungi (105, 106). 
One of the markers for Th17 cells is the transcription factor retinoid orphan receptor 
gamma T (RORγT) (107). Th17 cells have been associated with several autoimmune 
and inflammatory disorders, e.g. rheumatic arthritis, asthma and chronic obstructive 
pulmonary disease (COPD), where an accumulation of Th17 has been reported (108-
111). 
 
 
1.2.7 CD8+ T cells 
CD8+ T cells, i.e. CTLs, kill viruses and intracellular pathogens. They recognize 
antigens presented by HLA class I molecules (112). Upon stimulation, the CD8+ T 
cells differentiate into effector CD8+ T cells able to induce cell death; either through 
release of cytotoxic molecules such as perforin (113) or through binding to death 
receptors (Fas) on target cells and thereby stimulate apoptosis (114). Like CD4+ T 
cells, CD8+ T cells can upon stimulation by cytokines differentiate into T cytotoxic 
(Tc) 1 or Tc 2 cells with a cytokine profile similar to Th1 and Th2 cells (115-117). 
 
 
1.2.8 T regulatory cells 
Tregs is a subset of T cells which balance inflammatory and antigen specific responses. 
Abnormalities in the function of Tregs have been described in many autoimmune and 
chronic inflammatory disorders (118-121). In the protection against potential hazardous 
self-reactive T cells and to maintain immunologic self-tolerance there a two systems 
involved, commonly referred to as central and peripheral tolerance. The system of 
central tolerance is localized to the thymus. Since some self-reactive T cells will escape 
there are additional defense mechanisms in the periphery. For the peripheral tolerance 
the Tregs play an important role (122). Tregs develop in the thymus and characteristic 
for them is their lack of proliferative response towards antigenic stimulation. Instead, 
the Tregs suppress the proliferation of naïve T cells that respond to self-peptides (123). 
 
The first research about Tregs began with studies of cell induced multiorgan 
autoimmunity in recipient animals by adoptive transfer of T cells depleted of 
CD4+CD25+ (124). Tregs were therefore initially described as CD4+CD25+ T cells, 
which constitute 5-10% of all CD4+ T cells. Later, it was shown that they specifically 
express the transcription factor forkhead box protein 3 (FOXP3), today used as a 
marker for Tregs (119, 125-128). The transcription factor FOXP3 is critical for the 
development and function of Tregs (129). There is a rare disease in humans caused by a 
mutation in the FOXP3 gene named IPEX (immunodysregulation, polyendocrinopathy, 
enteropathy, X-linked) associated with severe autoimmunity (130, 131).  
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Normally functioning Tregs are proposed to use four suppressive mechanisms; by 
expression of the inhibitory cytokines IL-10, IL-35 and transforming growth factor-β 
(TGF-β) (132-135), via cytolysis (136), through consuming IL-2 produced by effector 
T cells and thereby starve the self-reactive T cells, leading to a decrease in T cell 
activity and proliferation (137, 138) and by inhibition of dendritic cell maturation and 
function (Figure 3) (139, 140).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Basic mechanisms used by Tregs: a) by expression of the inhibitory cytokines IL-10, IL-35 and 
TGF-β, b) via cytolysis, c) through consumption of IL-2, d) by inhibition of dendritic cells maturation 
and function.  Adopted from Vignali et al (141). 
 
The Tregs developed in the thymus are said to be natural occurring Tregs but there are 
also other subsets of Tregs, generated from mature T cell populations under certain 
conditions of antigenic stimulation such as infection. These adaptive Tregs produce 
anti-inflammatory cytokines which inhibit inflammation (142, 143) and they include 
IL-10 secreting T regulatory (Tr)1 cells, inducible FOXP3+
 
Tregs, Th3 cells (producing 
TGF-β) and double negative Tregs (144). They are believed to be induced by DCs with 
an activation status distinct from the DCs that promote differentiation of T cells into 
Th1 or Th2 cells (145).  
 
 
1.2.9 B cells 
B cells produce antibodies, known as immunoglobulins, and also function as APCs. 
The activation of B cells is either performed in a T cell dependent or a T cell 
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independent way. Upon the T cell-dependent activation the B cell will first internalize 
an antigen bound to the B cell receptor (BCR) and thereafter process it and then present 
parts of it as peptides bound to the B cell´s HLA class II molecule. The T cell that binds 
to this complex consisting of an antigen and HLA class II molecule will activate the B 
cell. B cells are sometimes also activated in a T cell independent way by binding 
directly to an antigen (146, 147). Activated B cells will transform into plasma cells able 
to produce antibodies and some undergo immunoglobulin (Ig) class switch to become 
more effector specialized (148). There are also B cells which will become long-lived 
memory cells (149). 
 
 
1.3 THE RESPIRATORY SYSTEM 
The main function of the respiratory system is to supply the body with oxygen and 
exhale carbon dioxide. The respiratory system is divided into the upper and lower part. 
The upper part of the respiratory system consists of the nose, nasal cavity, pharynx and 
larynx. The lower parts include trachea, bronchi, bronchioles and where the alveoli are 
the most distal part (Figure 4). Gas exchange takes part in the small alveoli by passive 
diffusion (150).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Illustration of the respiratory system. 
 
Inflammatory diseases of the respiratory system can be either obstructive where 
inflammation leads to narrowing of the airways (e.g asthma and chronic obstructive 
pulmonary disease) (151) or restrictive i.e. interstitial lung diseases where the 
inflammation causes increased lung stiffness (e.g sarcoidosis and idiopatic pulmonary 
fibrosis) (152).  
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1.3.1    Lung immunity 
The epithelium that lines the bronchial tree represents the first defense against harmful 
agents in the lung and acts as a physical barrier. The epithelium in the upper airways is 
mainly built up by ciliated cells that transport particles away from the lungs. Between 
the ciliated cells there are mucus producing goblet cells which together with the cough 
reflex helps to protect the airways (Figure 5) (153). The Epithelial cells produce IgA 
which neutralizes toxins and viruses and blocks bacteria to entry across the epithelium 
(154). Epithelial cells also send out signals, i.e. chemokines, which lead to recruitment 
of inflammatory cells into the airways (155). Important APCs in the lung are the DCs 
that upon inflammatory stimulation will migrate to the hilar LNs and there activate T 
cells (156). Even for the initial activation of DCs are the multifunctional epithelial cells 
important (155). For identification of pathogens, cells of the innate immune system in 
the lung have PPRs by which they recognize microbial products such as 
lipopolysaccharides (LPS), which are components in the membrane of gram-negative 
bacteria (157). The key mediators of the adaptive immune system in the lung are the 
lymphocytes which directly influence important events in pulmonary inflammation and 
repair (158). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Illustration of airway epithelia. Adopted from Patton et al (159). 
 
Macrophages are the predominant cells in the airways of the healthy lung. They are 
except from being phagocytes able to engulf harmful foreign particles such as bacteria 
and dead or dying cells, also able to secrete pro-inflammatory mediators i.e. cytokines 
and chemokines. These signal proteins are important for the recruitment of other 
immune cells (158). Macrophages arise originally from monocytes and are a very 
heterogeneous population. Based on the anatomical location in the lung, there are 
alveolar, interstitial and intravascular macrophages, all with different functions (160).  
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1.3.2 Interstitial lung diseases 
Interstitial lung diseases (ILD) consist of a heterogeneous group of parenchymal lung 
disorders. Some ILDs are caused by inhaled organic or inorganic substances, e.g. 
hypersensitivity pneumonitis and asbestosis. Others are parts of a rheumatic systemic 
disease and interstitial pulmonary infiltrates may occur in patients with for example 
rheumatic arthritis and scleroderma. Furthermore, drugs used in the treatment of 
rheumatic systemic diseases sometimes cause ILD themselves (161).  It is often not 
possible to differentiate between the types of ILDs with just a histological sample. 
Therefore, a good patient history and a careful examination of the patient are important. 
Questions that could give valuable information are for example about exposure to 
organic or inorganic substances and what medicines the patient takes. Investigation 
methods that can be essential in the diagnostic procedure are high resolution computed 
tomography (HRCT), bronchoalveolar lavage (BAL) and sometimes an open lung 
biopsy is required (162). Since the accumulated cells in the lung differ between ILDs, 
the findings in BAL may give guidance (163-165). 
 
 
1.3.3 Bronchoalveolar lavage 
The development of the technique with flexible bronchoscope and BAL has made it 
possible to study inflammatory cells in the lung. The method is safe and non-invasive 
and has been used since the late 1960s (166). To perform a BAL, saline solution is first 
installed via a bronchoscope in a selected location in the lung and thereafter as much as 
possible of the fluid is aspirated. The BAL is later analyzed with regard on how many 
percent there are of macrophages, neutrophils, eosinophils or lymphocytes (167). The 
results can be indicative or diagnostic for certain diseases together with findings from 
for example chest X-ray. In the healthy lung, the macrophages are the predominant cell 
population found in bronchoalveolar lavage  fluid (BALF) (168). In diseases such as 
sarcoidosis and hypersensitivity pneumonitis there is instead an increased percentage of 
lymphocytes, consisting mainly of T cells (169). In infectious diseases of the lower 
respiratory tract the number of neutrophils are usually increased (170), which is also the 
major lavage finding in patients with idiopathic pulmonary fibrosis (171). Except from 
counting the cells can analysis of cell-surface markers via a fluorescence-activated cell 
sorting (FACS) machine of BALF be of diagnostic help. Lymphocytes can for example 
be marked for CD4 and CD8 and where a CD4/CD8-ratio >3,5  strongly supports the 
sarcoidosis diagnosis (165).  
 
 
1.3.4 Endoscopic ultrasound guided fine-needle aspiration 
As a complement to bronchoscopy it is often of differential diagnostic interest to 
examine enlarged mediastinal LNs in patients with pulmonary infiltrates. Until 
recently, sampling of mediastinal LNs has required mediastinoscopy (172). Therefore, 
the availability of the less invasive method with endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA) via esophagus has become a valuable tool for the 
diagnostic procedure. The specificity and sensitivity in sarcoidosis patients have been 
shown to be 94% and 100%, respectively (173). Another way to take samples from the 
mediastinal LN is via endobronchial ultrasound guided transbronchial needle aspiration 
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(EBUS-TBNA). For the choice of method it is important to determine the position of 
the mediastinal LNs since some are possible to reach only via EUS-FNA, while others 
only can be accessed via  EBUS-TBNA (174). 
 
 
1.4 SARCOIDOSIS 
1.4.1    Epidemiology 
Sarcoidosis affects mainly young adults (25-35 years) with a second peak in women 
aged 45-65 (175). The risk of contracting sarcoidosis is higher for non-smokers than 
smokers  (176). In Sweden there are approximately 1 500 - 2000 people diagnosed 
annually with sarcoidosis (175). Sarcoidosis  is found throughout the world, but the 
frequency varies between different countries and ethnic groups (177). Afro-Americans 
are for example diagnosed three times more often than Caucasians and often get a more 
aggressive form of disease (178-182). Another example of differences between ethnic 
groups is the ocular manifestation uveitis, where the anterior form is reported to be 
more common in Afro-Americans (70-75%) while posterior uveitis is more often seen 
in Caucasians (65-83%) (183). Moreover, eye symptoms are much more frequently 
seen in Orientals in comparison to Scandinavians where instead Löfgren´s syndrome 
(LS) with bilateral hilar lymphadenopathy (BHL), fever and erythema nodosum and/or 
ankle arthritis is common (184-186).  There is also a seasonal variation in the onset of 
LS with two peaks, a first in January and a second in April and May (187, 188). 
Moreover, cardiac sarcoidosis is several times more frequent in Japan where it is the 
leading cause of death related to sarcoidosis (189). Elsewhere, respiratory failure is the 
most common cause. The overall mortality rate due to sarcoidosis is believed to be 
between 1 and 5 % (190).  
 
 
1.4.2    Etiology 
The etiology of sarcoidosis is still unknown, but there are several antigens proposed 
such as organic and inorganic particles, for example insecticides (191-194).  
Furthermore, there are data supporting that mycobacteria may be a triggering factor of 
sarcoidosis (195, 196). Studies have shown that lung and blood CD4+ and CD8+ T 
cells from sarcoidosis patients respond to multiple mycobacterial peptides (197, 198) 
and one identified candidate antigen is the Mycobacterium tuberculosis catalase-
peroxidase (mKatG) protein (199, 200). There are also reports about other bacteria 
associated with sarcoidosis such as propionibacterium acne (201, 202). Furthermore, 
differences between ethnic groups indicate that genetic factors play an important role 
for the risk of developing disease (203, 204) 
 
 
1.4.3  Genetic factors 
Genetic factors influence the clinical picture seen in sarcoidosis and especially the 
genes localized in the HLA region on chromosome six are believed to be of importance 
(205). In sarcoidosis, there are associations reported to both HLA class I and II genes 
(204, 206, 207) as well as to the genes involved in the activation of T cells and 
macrophages (208-210). One example of a HLA class II allele linked to sarcoidosis is 
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HLA-DRB1*03 associated with LS (188).  LS is commonly seen in Scandinavia but 
very rare in patients of Japanese origin in whom the HLA-DRB1*03 allele also is 
virtually missing (211, 212). In LS patients the HLA-DRB1*03 allele strongly 
influences the disease course with complete recovery within two years in almost all 
DRB1*03 positive patients, but only in half of the DRB1*03 negative patients (188). In 
contrast, the allele HLA-DRB1*15  is associated with a non-resolving disease in 
sarcoidosis (213). Furthermore, there is a strong association between HLA-DRB1*03 
and an oligoclonal expansion in BALF of CD4+
 
T cells expressing a TCR V gene 
segment termed AV2S3 (214). A similar accumulation of TCR AV2S3+ T cells in 
BALF is also seen in HLA-DRB1*13 positive patients (215, 216).  This correlation 
likely occurs because HLA-DRB1 *13 positive patients sometimes carry the HLA-
DRB3*0101 allele, which is known to be structurally similar to HLA-DRB1*0301 and 
therefore able to present comparable antigenic peptides (217). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  A simplified map over the HLA-region.  
 
 
There are also other genes closely linked to the HLA class II alleles that have been 
associated with sarcoidosis (Figure 6). Examples are the associations between uveitis 
caused by sarcoidosis and the heat shock protein (HSP)70/Hom rs2075800 G allele in 
patients from the United Kingdom and  Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) 
gene polymorphism in patients from Japan (218, 219). Furthermore, mutation in the 
Butyrophilin-like 2 gene (BTNL2) located close to the HLA genes has also been 
associated with an increased risk for sarcoidosis. The BTNL2 gene is thought to 
influence T cell activation and regulation (220). There are also reports about a higher 
frequency of the TNF allele TNF-A2 in patients with LS (221, 222). Moreover, it has 
been reported about associations between complement C4 and sarcoidosis (223). The 
role of linkage disequilibrium (LD), defined as a tendency for genetic variants located 
close to each other on the same chromosome to be associated within a population more 
often than if they were unlinked, have been discussed in sarcoidosis. Because of the 
strong LD within the HLA-region there are difficulties to determine which gene/s 
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represents the primary association and whether nearby located non-HLA genes  have 
any role  (224). 
 
 
1.4.4 Pathogenesis 
Sarcoidosis is a multisystem inflammatory disease of undetermined etiology. In the 
lungs of sarcoidosis patients there is commonly seen an increased percentage of 
lymphocytes, causing alveolitis. Among the lymphocytes found in BALF there are 
usually more CD4+ T cells then CD8+ T cells. The CD4+ T cells consist mainly of Th1 
lymphocytes, reflected by a cytokine profile with high levels of IL-2 and IFN-γ (225-
231). Further, cell surface markers of activation/differentiation on the CD4+ T cells 
such as CD69 and CD27 in bronchoalveolar lavage fluid (BALF) of patients with 
sarcoidosis show that these T cells are highly activated (232). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  T cell receptor with the V-segment AV2S3. 
 
 
Another marker of active disease in BALF of sarcoidosis patients is the expansion 
(>10%) of T cells expressing the T cell receptor V gene segment AV2S3 which are 
seen in patients who are HLA-DRB1*03 positive (Figure 7). The accumulation of 
AV2S3+ T cells in BALF is believed to be due to a response against a specific antigen 
(232). However, the expansion is oligoclonal since the α-chain could be paired with 
different β-chains (233). Analysis of cell-surface markers on AV2S3+ T cells together 
with the intracellular marker FOXP3 show that these AV2S3+ T cells are highly 
activated effector cells and not Tregs (234). Moreover, an increased percentage of  
AV2S3+ T cells in sarcoidosis is  associated with a better prognosis (235). The ratio of 
AV2S3+ T cell is later normalized when the patient has recovered (185). 
 
The CD8+ T cells found in BALF of sarcoidosis patients are also highly activated with 
a high capacity to produce IFN-γ  after in vitro stimulation,  which is even more 
pronounced for the CD8+  T cells compared to the CD4+ T cells (230). In sarcoidosis, 
there are also activated B-cells, probable as a result of an increased cytokine secretion 
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by the T cells. This leads to production of autoantibodies which form the immune 
complexes associated with erythema nodosum seen in patients with LS (236). 
 
In sarcoidosis, not only the lymphocytes are important for the disease course but also 
the macrophages. The production of the pro-inflammatory cytokine TNF-α by 
macrophages is central for the formation of granulomas seen in sarcoidosis. The level 
of TNF-α is found to be increased in sarcoidosis patients with active disease (237-239). 
It has been suggested that Tregs in patients with sarcoidosis have reduced inhibitory 
capacities (240, 241) and are unable to inhibit the production of TNF-α (242). The 
activated macrophages in the lungs of sarcoidosis patients also overproduce 1,25-
dihydroxy-vitamin D3 (calcitriol) which leads to an increased absorption of calcium in 
the gut, sometimes leading to hypercalcemia (243). 
 
Characteristic for sarcoidosis is the typically found non-necrotizing granulomas. In 
infectious diseases, the formation of granulomas for example in Tuberculosis is to 
prevent spreading of harmful antigens that the body cannot eliminate. In sarcoidosis, 
the function of the granulomas is not believed to be protective, but instead contribute to 
the tissue pathology. There are other systemic non-infectious diseases that also go with 
granuloma formation. However, typically for sarcoidosis is the presence of 
multinucleated giant cells in the granulomas. In sarcoidosis, the granulomas are formed 
by an aggregation of lymphocytes, macrophages, epitheloid cell, mast cells and 
fibroblasts (Figure 8). The epitheloid cells of the granulomas overproduce angiotensin-
converting enzyme (ACE), and an elevated ACE level is therefore common in 
sarcoidosis patients (244). The ACE level is believed to reflect the total burden of 
granulomas (245).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Granuloma formation. Adopted from Grunewald et al  (246). 
 
The granuloma formation is initiated by an accumulation of CD4+ T cells and 
macrophages (204, 247). The CD4+ T cells are found mainly within the central portion 
of the granuloma and in the periphery there are CD8+ T cells. In a sarcoid granuloma 
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that undergoes fibrotic changes the process starts in the border and travels centrally. 
CD8+ T cells, fibroblasts and regulatory cells will become more prominent as the 
activity of the granuloma diminishes and fibrosis ensues (190, 248-250). In patients 
who develop fibrosis in their granulomas it has been suggested that there is a switch 
from a Th1 phenotype to Th2 phenotype, and where the Th2 cytokines IL-4 and IL-13 
functions as chemo-attractants for the fibroblasts (251). In summary, pulmonary 
sarcoidosis begins as an alveolitis with development towards a multinucleated giant cell 
granulomatous disease, followed by either resolution with no or little sequele, or 
progressive fibrosis leading to an end-stage lung disease. 
 
 
1.4.5    Clinical features 
Sarcoidosis is a granulomatous disease that affects the lungs and/or intrathoracic LNs in 
more than 90% of all cases, but almost any organ can be involved such as the skin, 
peripheral LNs, eyes, nervous system, kidneys, heart, liver, spleen and bone marrow 
(252, 253). A specific phenotype of sarcoidosis is LS, characterized by acute disease 
onset with erythema nodosum and/or ankle arthritis, fever and bilateral hilar 
lymphadenopathy and occasionally with pulmonary infiltrates (254, 255). LS was first 
described by the Swedish physician Sven Löfgren in 1952 who had studied patients 
with erythema nodosum and its various causes. He described a condition that he termed 
“the bilateral hilar lymphoma syndrome”, later known as LS (256). LS usually has a 
very favorable outcome with a spontaneous and complete resolution (188). However, 
the most common variant of sarcoidosis is non-LS with a more insidious onset with dry 
cough and fatigue (252).  
 
Extra-pulmonary manifestations are commonly seen in patients with sarcoidosis and 
one example is cardiac involvement which can manifest itself in the form of benign 
arrhythmias, but in the worst case as sudden death (257-259). Findings from autopsy 
studies indicate that the incidence of cardiac sarcoidosis (CS) likely is higher than what 
is diagnosed in the clinic (189, 260). Another extra-pulmonary manifestation is ocular 
sarcoidosis and where uveitis is the most common  manifestation (261). Examples of 
other ocular engagements are lacrimal gland inflammation and conjunctival granulomas 
(262). The ocular manifestation uveitis is associated with a distinct phenotype of 
sarcoidosis named Heerfordt´s syndrome (HS). The complete form of HS consists of 
uveitis, parotid and/or salivary gland enlargement and cranial nerve palsy, especially 
the facial, and also fever (263). In addition, engagement of the cranial nerves is also the 
most common form of neurosarcoidosis (264-266). Furthermore, the presence of skin 
involvement in sarcoidosis can be very unsightly if localized to the face and can 
sometimes appear in old scars. However, skin reactions seen in patients with LS, i.e. 
erythema nodosum, usually disappears within three weeks (253). Findings of increased 
levels of creatinine may indicate kidney involvement (267, 268). 
 
 
1.4.6 Diagnosis 
The diagnosis of sarcoidosis is based on evaluation of clinical symptoms, chest X-ray, 
laboratory findings and if possible positive biopsies showing the characteristic 
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granulomas. Chest-X-ray  in sarcoidosis patients are divided into five stages (Table 1) 
(246).  
 
 
Table 1. Chest radiographic staging 
Stage             Finding 
0 Normal chest radiograph 
I Bilateral hilar lymphadenopathy (BHL) 
II Parenchymal infiltrations with BHL 
III Parenchymal infiltrations without BHL 
IV Volume reduction and signs of fibrosis 
 
 
The investigation of sarcoidosis patients normally includes measurements of the lung 
function, and where static and dynamic spirometry tests usually reveal signs of a 
restrictive and/or obstructive disease (269). Often is also a bronchoscopy with BAL 
performed and where the cell analysis from the BAL fluid typically show an 
accumulation of CD4+ T lymphocytes resulting in an increased CD4/CD8-ratio >3.5. 
In patients with LS who have a characteristic clinical and radiological picture, an 
increased CD4/CD8 -ratio is considered to be diagnostic and equivalent with a positive 
biopsy (165).  
 
A laboratory parameter that strengthens the diagnosis, even if not specific for 
sarcoidosis, is an increased level of ACE (270). ACE is produced by epitheloid cells in 
the sarcoid granulomas (271) . The ACE level is believed to reflect the granuloma 
burden (272). It has therefore been suggested that the ACE level can be used to predict 
relapse or improvement of sarcoidosis (270, 273). Further, liver enzymes are usually 
controlled at onset of disease to see if signs of hepatic involvement, but not all patients 
with engagement of the liver have an abnormal liver function (274, 275). Enlargement 
of the liver on an abdominal CT scan can also indicate liver involvement (276). Further, 
creatinine is controlled to see if the kidneys are affected which could result in kidney 
failure (268). The levels of calcium is controlled in both blood and urine, since 
hypercalciuria is more commonly seen than hypercalcemia (277). In addition, it should 
be kept in mind that hypercalcemia can be seen in also in several other diseases. 
 
In patients investigated for sarcoidosis, efforts are made to obtain histological evidence 
in the form of a positive biopsy showing the typical granulomas, especially in patients 
with non-LS. If possible, the biopsies are taken from easily accessible locals such as 
peripheral enlarged LNs or skin lesions secondary to sarcoidosis. An alternative are to 
take samples from mediastinal LNs which until recently have required mediastinoscopy 
(172). Therefore, the availability of the less invasive technique with EUS-FNA via 
esophagus has become a valuable tool in the diagnostic procedure (173). A positive 
biopsy can be taken not only to ensure the diagnosis but also to confirm extra-
pulmonary engagement. However, there are extra-pulmonary manifestations difficult to 
confirm with a biopsy such as cardiac involvement and often are several different 
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investigation methods used instead. For example can 24-hour ambulatory 
electrocardiogram (ECG) show ventricular tachycardia, atrioventricular blocks or 
ventricular extra systoles (278, 279). Cardiovascular magnetic resonance (CMR) can 
detect edema as a sign of inflammation or show fibrotic changes (280-284). 
Furthermore, investigation with position emission tomography-computer tomography 
(PET / CT) can show defects in the uptake of contrast (285-289). A cardiac biopsy is an 
alternative in patients with a high suspicion of CS, but the chance to get representative 
samples with granulomas is low and not without risk (290). Thus, proposal for criteria 
of cardiac sarcoidosis have been developed as an alternative to the histological 
diagnosis (291). Other examples of organ manifestations where alternative criteria have 
been developed for the diagnosis are engagement of the eyes and nervous system (292, 
293). For the diagnosis of neurosarcoidosis can investigation with CMR be useful in the 
same way as for CS (294, 295).  
 
Important to remember is that there are other diseases that may be mistaken for 
sarcoidosis, for example lymphoma, tuberculosis, histoplasmosis, Wegners 
granulomatosis and chronic beryllium disease. Tests that can be used to exclude these 
diseases are needle aspiration or biopsies from enlarged LNs if there is a suspicion of 
lymphoma (296), culture  for mycobacteria can be taken to rule out tuberculosis,  
serology for histoplasmosis, blood test for detection of anti-neutrophil cytoplasmic 
antibodies (ANCA) in Wegners granulomatosis and beryllium lymphocyte proliferation 
test on blood or BALF for chronic beryllium disease (252).  
 
1.4.7 Treatment 
The disease course in sarcoidosis varies significantly, from complete resolution to 
pulmonary fibrosis with respiratory failure. Patients with LS usually have a very good 
prognosis and non-steroidal anti-inflammatory drugs are often sufficient as 
symptomatic treatment in the initial acute phase (188).  There are patients with 
sarcoidosis who recover spontaneously, but also those who develop chronic disease 
with pulmonary fibrosis leading to respiratory failure. The first line of treatment for 
these patients is oral corticosteroids. Treatment is usually initiated if there is a 
progressive loss of lung function or extra-pulmonary manifestations such as 
hypercalcemia, involvement of the heart or nervous system (252). Treatment with 
corticosteroids is in general considered to have a suppressive effect in the acute phase 
but long term benefits are less certain (297-299). In addition, many patients with 
pulmonary sarcoidosis do also improve spontaneously (300). For individuals that 
require high doses of corticosteroids, methotrexat may be added in order to reduce the 
dose of cortisone (301).  Treatment with TNF-α inhibitors as an alternative are still 
under evaluation (253, 302). However, no study has clearly demonstrated that 
medication prevents the progression of pulmonary inflammation towards fibrotic 
changes (303). In patients with cardiac involvement is the aim with corticosteroid 
therapy to prevent development of heart failure and to reduce disturbances in the 
cardiac conduction system which in the worst case can lead to life-threatening 
arrhythmias. Medication is usually continued for a minimum of one year but may be 
discontinued if there is a lack of efficacy or if the pathologic changes completely 
disappear. (284). Furthermore, inhaled corticosteroids may ease the symptoms in 
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patients with cough (304). For patients with ocular engagement, topical corticosteroids 
may sometimes be sufficient for maintenance (186).  
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2 AIMS OF THIS THESIS 
 
The general aim of the work presented in this thesis was to study risk factors for 
different organ involvements and markers of importance for the inflammatory response 
seen in sarcoidosis patients. 
 
Specific aims were: 
 To analyze links between HLA-DRB1* alleles and symptoms associated with 
Heerfordt´s syndrome such as uveitis, engagement of parotid and/or salivary 
glands or cranial nerve palsy, with particular focus on uveitis.  
 
 To concomitantly compare the adaptive immune response seen in BALF, blood 
and lymph nodes of sarcoidosis patients. Furthermore to investigate if the 
increased CD4/CD8-ratio found in BALF is reflected by a similar type of 
accumulation of CD4+ T cells in the thoracic lymph nodes. 
 
 To examine the role of pathologic ECG changes for the risk of developing 
cardiac sarcoidosis and as well phenotypic and genotypic factors.  
 
 To investigate the role of both single and pairs of HLA-DRB1* alleles for the 
risk of developing extra-pulmonary manifestations in sarcoidosis patients. 
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3 METHODS 
 
The present thesis is based on studies of human samples, including analyses of BALF, 
blood and lymph nodes (LN). The studies were performed after approval by the local 
ethics committee and all subjects included in the studies gave their written informed 
consent to participate. 
 
 
3.1 SUBJECTS (PAPER I-V) 
The included sarcoidosis patients were all, except for in paper II, consecutively 
recruited after referral to the Chest Clinics at either Karolinska University Hospital in 
Solna or Södersjukhuset, Sweden, for diagnostic investigation. In paper II, only 
patients with a chest X-ray showing radiological stage I (bilateral hilar 
lymphadenopathy) or II (bilateral lymphadenopathy with parenchymal infiltrates) were 
included. In the other three papers were also patients included with stage III (solely 
parenchymal infiltrates) and IV (volume reduction). All patients in paper I-IV were 
HLA-typed except from three patients in paper III. Patients were diagnosed with 
sarcoidosis in paper I-IV through typical clinical and radiographic manifestations, 
findings at bronchoscopy with BAL including an elevated CD4/CD8-ratio and positive 
biopsies, using the criteria outlined by the World Association of Sarcoidosis and other 
Granulomatous disorders (WASOG) (190). Löfgrens´ syndrome (LS) was defined as 
bilateral hilar lymphadenopathy with or without parenchymal infiltration, fever, 
erythema nodosum and/or ankle arthritis. Clinically resolved disease was defined as 
disappearance of symptoms (dry cough, fever, fatigue and extra pulmonary 
manifestations) and a normalized chest X-ray. For non-resolving disease the criteria 
outlined by Costabel et al. were used (305). Ever smokers were defined as patients who 
previously had smoked or were current smokers. Healthy subjects were included as 
controls in paper I and IV for comparisons regarding the frequency of HLA-DRB1* 
alleles. In paper II a control group was included with six patients who had enlarged 
superficial LNs, punctured for diagnostic purposes with findings of unspecific 
inflammation.   
 
 
3.2 BRONCHOALVEOLAR LAVAGE (PAPER II) 
The BAL was performed according to procedures earlier described (306). The BALF 
was afterwards kept on ice, and later strained through a Dacron net (Millipore, Cork, 
Ireland) and centrifuged. Thereafter the supernatants were removed. The cell pellet was 
resuspended in PBS for further analyzes. Cell differential counts were determined by 
May-Grünwald Giemsa staining of cytospin slides. 
 
   
3.3 ENDOSCOPIC ULTRASOUND GUIDED FINE-NEEDLE ASPIRATON 
(PAPER II) 
EUS-FNA was carried out via an esofagus ultrasound endoscope and aspirates were 
obtained with a 25-gauge needle. Smears of aspirates obtained by EUS-FNA were 
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initially air-dried and evaluated on-site by using a modified May-Grünwald 
Giemsa quick staining method. 
 
 
3.4 FLOW CYTOMETRY (PAPER II) 
The cell pellet from the centrifuged BALF was resuspended in PBS and antibodies 
were added, and thereafter incubated at 4
o
 C for 20 minutes. Monoclonal antibodies 
used for surface staining were CD4, CD8, CD69, CD27 (BD Bioscience, Mountain 
View, CA, U.S.A.) and AV2S3 (Thermo scientific, Waltham, MA, U.S.A.). After 
incubation, the cells were washed twice. Surface markers expressed on T cells were 
analyzed with flow cytometry using a FACS CANTO II flow cytometer (BD 
Bioscience). Data were processed with FACS Diva 6.1.2 software (BD Bioscience). 
 
The blood was stained with the same mixture of antibodies as for BALF and incubated 
at room temperature for 20 minutes. Thereafter, erythrocytes were removed through 
incubation with lysing solution (BD Bioscience) for 8 minutes. The cells were 
afterwards washed twice and analyzed by flow cytometry. Data were processed with 
FACS Diva 6.1.2 software (BD Bioscience). 
 
Cells from LN were stained with surface markers using the same procedure as for 
BALF cells. Data were processed using FACS Diva 6.1.2 software (BD Bioscience) 
and Infinicyt software (Cytognos, Salamanca, Spain). 
 
A FOXP3 staining kit (eBioscience, San Diego, CA, USA) was used for intracellular 
staining. First, the cells were fixed and permeabilized for 45 minutes at 4
o
 C in dark. 
Then washed twice with permeabilization buffer and incubated with 2% rat serum for 
15 minutes. Next, the cells were stained intracellularly with anti-FOXP3 and incubated 
for 30 minutes at 4
o
 C. Finally, the cells were washed twice with permeabilization 
buffer and analyzed by flow cytometry. 
 
 
3.5 HUMAN LEUKOCYTE ANTIGEN TYPING (PAPER I-V) 
HLA-class II (HLA-DRB1) typing of patients paper I-IV was done on DNA from 
blood samples through the use of polymerase chain reaction (PCR) and amplification 
with sequence-specific primers (SSP) (307). For the controls in paper I and IV the 
majority was HLA-typed using PCR-SSP but some of the HLA-DRB1* alleles were 
determined with restriction length polymorphism (308, 309). 
 
 
3.6 DEFINITION OF ORGAN INVOLVEMENT (PAPER I-V) 
A positive biopsy was in general required for patients with engagement of the skin, 
LNs, parotid and/or salivary glands, liver, spleen and bone marrow. Patients diagnosed 
with sarcoidosis were defined to have hypercalcemia and/or kidney involvement if they 
had repeated blood samples with p-calcium >2.60 mmol/L and/or p-creatinine > 90 
µmol/L for women and > 100 for men. The criteria outlined by Herbort et al (293) were 
used for ocular sarcoidosis in paper I and IV and the Japanese guidelines by Hiraga et 
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al (291) was used for cardiac sarcoidosis in paper III and IV. Patients were defined as 
having neurosarcoidosis according to Zajicek criteria in paper I and IV (292). 
Erythema nodosum and ankle arthritis in patients with LS were excluded from the 
extra-pulmonary manifestations in paper IV. 
 
 
3.7 STATISTICAL ANALYSIS (PAPER I-V) 
In paper I and II statistical analyses and graphs were performed with Graph Pad Prism 
4.03  (GraphPad Software Inc., San Diego, CA, USA) and in paper III and IV with 
Graph Pad Prism 6. For comparison of different allele frequencies, p<0.003 was 
regarded as significant [after Bonferroni correction number of alleles (n=13) i.e. 
dividing 0.05 with 13] and for combinations of HLA-alleles p<0.0005 (n=91). 
Otherwise p<0.05 was regarded as significant. The non-parametric Mann Whitney test, 
Friedman´s test followed by Dunn´s post-test, was used when appropriate. Correlations 
were analyzed using Spearman´s rank correlation test. HLA-data were analyzed by 
Chi-square test or in the case of small numbers by Fisher´s Exact Test. In paper IV 
relative risk (RR) was calculated from the cross product ratio of the data of interest. In 
paper IV sensitivity, specificity, positive and negative predictive value of ECG-
screening for identifying the presence or absence of CS were calculated considering a 
patient with a pathologic ECG diagnosed with CS as true positive and false positive if 
the ECG was pathologic but CS was not diagnosed during the follow-up.  
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4 RESULTS AND DISCUSSION 
 
4.1 INTRODUCTION 
Sarcoidosis is a systemic granulomatous disease that in more than 90% affects the 
lungs and/or intrathoracic LNs, and almost any organ such as skin, peripheral LNs,  
eyes and heart can be involved (252, 253). Genetic factors have an influence on the 
clinical picture seen in sarcoidosis (310-313). For example is the HLA-DRB1*0301 
allele overrepresented in patients with LS (314, 315). Therefore, it could be other 
specific forms of sarcoidosis where the HLA-DRB1 alleles are of importance. 
Characteristic for sarcoidosis is an increased percentage of CD4+ T cells in BALF 
(165). In HLA-DRB1*03 positive patients there is an accumulation among the CD4+ T 
cells of AV2S3+ T cells (>10%) (214). However, it has not been known whether cells 
found in BALF reflect those found in the enlarged regional LNs. Engagement of the 
heart is a potentially life-threatening condition. Previously, there has been no consensus 
with regard to the optimal clinical evaluation and diagnostic procedures of patients with 
suspected cardiac involvement in sarcoidosis, and improvement in patient evaluation 
strategies might help defining the patients at high risk (281). In type 1 diabetes is the 
HLA-DRB1 alleles *03 and *04 separately associated with an increased risk, but were 
the risk is highest for those who carry both the alleles (316). The role of HLA-DRB1 
combinations in sarcoidosis has not previously been thoroughly investigated. 
 
The aim of this thesis was therefore to further evaluate risk factors for distinct clinical 
manifestations of sarcoidosis and the inflammatory cell response seen in sarcoidosis. 
 
 
4.2 SYMPTOMS ASSOCIATED WITH HEERFORDT´S SYNDROME 
(PAPER I) 
HS originally termed “Febris uvea-parotidea subchronica”, is a specific phenotype of 
sarcoidosis that was characterized by Christian Heerfordt in 1909 (317). He described 
three patients with uveitis, parotid swelling, cranial nerve palsy and fever. However, 
HS was first in 1937 classified as a distinct manifestation of sarcoidosis by Jan 
Waldenström (318).  Since HS like LS is a specific phenotype of sarcoidosis, we 
wanted to investigate whether there also here were links to the HLA-DRB1* alleles. 
 
One thousand patients with sarcoidosis, out of which 83 had one or more symptoms 
associated with HS, were included in the study together with a group of 2000 healthy 
individuals from the same population, matched for gender and age. HLA-DRB1* 
alleles were determined for all individuals and comparisons were made between 
patients with HS associated symptoms and healthy controls.   
 
 
4.2.1 Risk factors for Heerfordt´s syndrome  
The complete form of HS is rare and we choose therefore in accordance with 
Scadding´s modification of HS, to divide patients as having incomplete or complete 
forms of HS (263). We thus added patients with only uveitis and patients without 
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uveitis but with one or both of the other two manifestations, i.e. engagement of parotid 
and/or salivary glands and cranial nerve palsy, and described them as having symptoms 
associated with HS. We found in patients with HS associated manifestations an 
overrepresentation of HLA-DRB1*04, and the risk seemed to be even higher in 
homozygote patients.  HLA-DRB1*04 has otherwise, in this as well as in previous 
studies, shown to be protective against overall sarcoidosis (319, 320). In patients with 
HS associated symptoms, ocular engagement was the most common manifestation. 
Half of the patients with parotid and/or salivary gland enlargement did not have ocular 
engagement and more than half of them were HLA-DRB1*04 positive. This indicate 
that the connection to HLA-DRB1*04 is not only driven by uveitis. The fact that 
almost all patients with cranial nerve palsy also had uveitis strengthen that it is a part of 
a syndrome. Further, about half of the patients with other ocular inflammatory 
manifestations than uveitis were also HLA-DRB1*04 positive. Therefore, the 
correlation seems not to be limited only to uveitis, but instead include all ocular 
manifestations. 
 
Our results of a genetic association to the different organ manifestations seen in HS are 
supported by other studies. For example have associations between HLA-DRB1*0401 
and ocular sarcoidosis been suggested, but in significantly smaller patient cohorts and 
where patients of different ethnic origins were included (310, 321). Further, 
correlations between HLA-DRB1* 0401 and involvement of parotid and salivary 
glands were noted in a study by Rossman et al (310), however the correlation was 
significant only for Afro-Americans and not for Caucasians. In a more recent study by 
Sato et al, links between DRB1*0803 and neurosarcoidosis was reported in Japanese 
patients and between DRB1*0401/DQB1*0301 and uveitis in UK (321).  
 
One possible explanation to the genetic linkage to HLA-alleles is cross reactivity, i.e. 
that there are proteins for example in the eye that resembles the antigen which the 
immune system initially reacted against. HLA-DRB1*04 allows according to this 
theory an adequate antigen presentation of eye derived proteins. Since patients 
homozygous for HLA-DRB1*04 had an even higher risk for HS associated symptoms 
compared to heterozygous, those who are homozygous may have a more efficient 
antigen presentation, leading to an inflammatory reaction.   
 
In conclusion, with regard to our findings it seems reasonable to suggest that HLA-
DRB1*04 positive patients should be closely monitored for particularly uveitis, but also 
parotid and salivary gland enlargement as well as cranial nerve palsy.  
 
 
4.2.2 The protective role of human leukocyte antigens  
We also investigated if there were HLA alleles with a reduced risk for ocular 
engagement. We found that the presence of the HLA-DRB1*03 allele, which is 
associated with a good prognosis in Scandinavian patients (206, 315), was significantly 
reduced in patients with ocular sarcoidosis. However, in all patients the frequency of 
the allele was higher compared to healthy controls and seemed to be associated with an 
increased risk of contracting sarcoidosis.  Also HLA-DRB1*01,  previously found to be 
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strongly protective against non-LS was found to protect also against eye involvement 
(320). 
 
 
4.2.3 Ocular involvement and non-resolving disease 
Since the majority of the patients had ocular engagement we focused extra on this 
group. The prevalence of ocular sarcoidosis in our study was relatively low compared 
to what has been reported by others. One explanation may be that we had relatively 
strict criteria for the diagnosis of ocular sarcoidosis, and where only patients with 
obvious symptoms were examined for eye involvement. For example patients with 
conjunctivitis sicca were excluded in our study but included in others (322, 323). We 
also wanted to investigate if the HLA-DRB1*04 allele had any influence on the disease 
course. The majority of patients had been followed for at least two years, and there 
were no significant differences in outcome between the HLA-DRB1*04 positive or 
negative patients. Compared with patients without ocular sarcoidosis, patients with eye 
involvement had a significantly poorer prognosis with a higher frequency of non-
resolving disease. We concluded therefore that ocular engagement seems to be of 
greater prognostic importance than the HLA-DRB1* type. This in contrast to patients 
with LS, where the HLA-type (HLA-DRB1*03) is a prognostic marker (315).  
 
Ethnicity is also likely to have an impact on the prevalence of ocular sarcoidosis, and it 
is known that for example in Japan the frequency of ocular engagement is considerably 
higher than in Scandinavia (324). Most of the patients with ocular sarcoidosis in our 
study had non-resolving disease, which sharply differs from the Japanese sarcoidosis 
patients where ocular engagement often is associated with good prognosis (325). In a 
study by Pietinalho et al where Finnish and Japanese patients with sarcoidosis were 
compared, ocular sarcoidosis was found in more than half of the Japanese patients 
compared with 5 % in the Finnish cohort. The majority of the Japanese patients had a 
normalized chest radiograph after two years (324). In conclusion, involvement of 
ocular engagement in Scandinavian patients calls for increased awareness of possible 
non-resolving disease and a more intensive follow-up. 
 
 
4.3 T CELL PHENOTYPES FROM THREE COMPARTMENTS (PAPER II)  
Sarcoidosis is characterized by the formation of non-necrotizing granulomas in the 
affected organs and with an increased CD4/CD8-ratio in BALF (165). The increased 
ratio is caused by an accumulation of CD4+ T cells. In HLA-DRB1*0301 positive 
patients there is also an expansion of CD4+ T cells that express the TCR V-gene 
segment AV2S3 (68). Since accumulation of AV2S3+ T cells are associated with good 
prognosis, AV2S3+ T cells are proposed to be effector cells (234). However, it is not 
known whether the lymphocytes found in BALF simultaneously reflect those in the 
enlarged regional LNs. Therefore, we wanted to investigate and compare T cell 
phenotypes in BALF, blood and mediastinal LNs in patients with sarcoidosis. 
 
The fifteen included patients underwent clinical investigation including bronchoscopy 
with BAL. Blood samples were drawn simultaneously, and EUS-FNA of enlarged 
mediastinal LNs via esophagus was also performed. The cells from the three different 
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compartments were then stained with markers/antibodies and analyzed by flow 
cytometry. Analysis were performed regarding T cells (CD4+ and CD8+),  markers of 
activity (CD69), differentiation (CD27), T regulatory cells (FOXP3) and AV2S3+ cells. 
A control group was included with six patients who had enlarged superficial LNs, 
punctured for diagnostic purposes with findings of unspecific inflammation.   
 
 
4.3.1 CD4/CD8-ratio in lymph nodes of less diagnostic value  
In BALF of sarcoidosis patients a CD4/CD8-ratio >3.5 is used to strengthen the 
diagnosis (165). We wanted therefore to analyze if an elevated CD4/CD8-ratio in 
BALF correlates with a similar elevated CD4/CD8-ratio in the regional LNs. We found 
that the CD4+ T cells did accumulate in the LNs compared to peripheral blood, 
resulting in an elevated CD4/CD8 ratio in LN. However, the accumulation of CD4+ T 
cells in the LNs was not as pronounced as in BALF. An accumulation of CD4+ T cells 
was also seen in the controls´ LNs, in line with what has previously been reported 
(326). In summary, the CD4/CD8-ratio in LNs seems to be of less value as a diagnostic 
tool in comparison to findings in BALF in patients with a suspicion of sarcoidosis. 
 
 
4.3.2 Differentiated T cells in bronchoalveolar lavage fluid 
The cell surface marker CD27 is known to be expressed by naïve T cells and to be 
initially up-regulated during T cell activation but gradually down-regulated as the T 
cells differentiate and become capable to produce more cytokines (93). CD27 and other 
markers of activation such as CD69 are known to be expressed differently in 
sarcoidosis patients in comparison to healthy controls, indicating that CD4+ T cells in 
BALF  of sarcoidosis patients are more activated and differentiated (232). Therefore, 
we wanted to investigate the enlarged LNs and compare the findings with what is seen 
in BALF of sarcoidosis patients. Our results show that T cells are more differentiated in 
the peripheral airways than in the LNs and thus contributing to the exaggerated 
inflammation seen in the small airways. In sarcoidosis patients, a possible explanation 
to the excessive levels of CD4+ T cells in BALF in comparison to LNs and blood, may 
be that the CD4+ T cells activated in the LNs circulate through the bloodstream to the 
alveoli and there accumulate in response to an unknown antigen. In addition, our 
findings also show that not only CD4+ T cells, but also the CD8+ T cells are highly 
activated in the lungs of sarcoidosis patients. This is supported by a previous study that 
showed a high capacity of BALF CD8+ T cells to produce cytokine IFN-γ in 
sarcoidosis patients after in vitro stimulation, which was even more pronounced for 
CD8+ than CD4+ T cells (230).  
 
Mutations in the gene coding for FOXP3 has previously been associated with severe 
autoimmune diseases, illustrating the importance of T regulatory cells for which 
FOXP3 is a marker (131). Our results of an increased level of FOXP3+ T cells in LNs 
of sarcoidosis patients is also supported by findings from previous studies, though the 
authors then investigated LN biopsies while we analyzed aspirates from EUS-FNA 
(327). The similarity of the results, illustrates the clinical value of EUS-FNA, which is 
less invasive compared to taking biopsies from LNs through mediastinoscopy. For 
EUS-FNA we used a thin 25 gauge needle to avoid blood contamination of the 
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samples, but which at the same time was thick enough to provide sufficient cell 
material to obtain a definite diagnosis (328, 329). 
 
 
4.3.3 Specific T cells in bronchoalveolar lavage fluid 
Our group has previously shown that HLA-DRB1*03 positive patients of Scandinavian 
origin with sarcoidosis more or less always have an accumulation in the lungs of CD4+ 
T cells expressing the TCR V gene segment AV2S3 (defined as >10% of CD4+ T cells 
express AV2S3 in BALF) (215). In this study we found that in comparison to BALF, 
there was an absence of LN-accumulated AV2S3+ T cells, suggesting that the focus of 
the immune response is localized to the alveoli. This perhaps as a result of repeated 
inhalations of triggering antigens alternatively by protein deposits following a bacterial 
or viral infection. Further, our results show in patients who harbored an expansion of 
AV2S3+ T cells, an inverse relation between the frequency of BALF AV2S3+ T cells 
and the fraction of FOXP3 expressing BALF T cells. It has in previous studies been 
discussed that the AV2S3+ T cells appear to be effector cells, rather than regulatory 
cells (234, 241). In line with this hypothesis, patients with an expansion of AV2S3+ T 
cells in BALF may consequently be able to more efficiently eliminate a presumed 
sarcoidosis-specific antigen, and there is therefore less need of FOXP3 expressing T 
cells in such patients.  
 
 
4.4 RISK FACTORS FOR CARDIAC SARCOIDOSIS (PAPER III) 
Clinical manifestations in CS occurs in about 5%, but biopsy samples from deceased 
patients with sarcoidosis show that the incidence of cardiac involvement is likely to 
be higher (190, 260). The septum is commonly engaged in patients with CS, leading 
to damage of the conduction system (258). Engagement of the heart may therefore 
manifest itself as benign arrhythmias or give rise to severe conduction blocks and in 
worst case life threatening arrhythmias (259). The overall objective of this study of a 
large cohort of well-characterized Scandinavian patients with a primary diagnosis of 
sarcoidosis was to investigate the value of resting ECG and clinical symptoms for 
early identification of CS and to estimate their relative importance. In addition, 
different phenotypic and genotypic factors were also included in the analysis.  
A cohort of 1017 Caucasian patients with sarcoidosis were screened with ECG at 
disease onset and investigated for CS according to clinical routine.  
 
 
4.4.1 An abnormal electrocardiogram and cardiac sarcoidosis 
We found that CS was very rare in Caucasian sarcoidosis patients with a normal ECG 
at disease onset. The risk for CS was significantly higher in sarcoidosis patients 
presenting with a pathologic ECG, in particular if they simultaneously had cardiac 
related symptoms such as palpitations, pre-syncope or syncope. Furthermore, 
symptoms indicating CS may develop later on in the disease course and therefore 
repeated investigations with ECG may be needed (287). In our study the average 
patient had had sarcoidosis for a couple of years before the diagnosis of CS. In addition, 
even small ECG changes are important to take seriously since they later can progress. 
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In our material, CS with pathologic changes developed later on in three patients who 
initially had a normal ECG. Moreover, the frequency of CS in the whole study 
population may have been even higher than the one we noticed if we had investigated 
all patients with a pathologic ECG in a more extended way. However, it was not 
possible because of this study´s retrospective nature. Based on the results, it seems 
reasonable to suggest that all sarcoidosis patients who have a pathologic ECG should 
be further investigated for CS. Patients who have a normal ECG at first presentation 
and lack the above symptoms of suspected cardiac involvement appear to be at a low 
risk for CS. 
 
 
4.4.2 Additional risk factor for cardiac involvement 
We also found phenotypic and genotypic factors associated with a pathological ECG as 
well as with CS. For example there was a similar male dominance among patients with 
a pathologic ECG, as also seen in patients finally diagnosed with CS. This finding 
differs slightly from what was reported in a previous study of autopsy material from 
diseased sarcoidosis patients, where in Caucasians there were almost an equal number 
males and females with CS (189). In our study, an increased risk for a pathological 
ECG, and a similar tendency of an increased risk for CS, was seen in patients with 
parenchymal lung infiltrates, i.e. more advanced disease, on chest radiography. 
Moreover, LS patients had a significantly reduced risk for CS compared to non-LS 
patients. However, HLA-DRB1*03 negative LS patients need to be more closely 
controlled with respect to CS. This finding is consistent with the observation that 
Scandinavian LS patients, especially HLA-DRB1*03 positives, have a very favorable 
prognosis (188). A genotypic factor that seemed to be associated with CS was HLA-
DRB1*15 as half (50.0%) of the HLA-typed patients with CS had this allele compared 
to a third of the patients without CS (non-significant, probably due to the small number 
of patients with CS). In contrast, HLA-DRB1*01 seemed to protect against CS. 
However, these findings did not reach statistical significance probably due to too few 
observations. The finding of a genetic link is supported by  results from Japanese 
patients where HLA-DQB1*0601 was found to be significantly increased in patients 
with CS (330). In conclusion, male gender, advaned radiographic stages, non-LS and 
HLA-DRB1*15 call for an increased awareness of CS. 
 
 
 
4.5 EXTRA-PULMONARY MANIFESTATIONS AND HLA ALLELES 
(PAPER IV) 
The HLA-DRB1*03 allele is known to be overrepresented in patients with LS 
compared to healthy controls (314, 315). A genetic association is also found in patients 
with ocular sarcoidos, where there is an increased frequency of  HLA-DRB1*04 (213). 
We therefore aimed to further investigate the role of specific HLA alleles as well as 
combinations of HLA alleles for the risk of extra-pulmonary manifestation in 
sarcoidosis. 
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Thousand patients with sarcoidosis, out of which 288 had extra-pulmonary 
manifestations, were included in the study. There were 383 patients with LS and 617 
patients with non-LS. Extra-pulmonary manifestation was defined as an organ 
engagement secondary to the sarcoidosis disease, involving other organs than the lungs 
and/or thoracic lymph nodes but excluding erythema nodosum and ankle arthritis. The 
different organ manifestations studied were engagement of the skin, superficial LNs, 
eyes, nervous system, kidneys, hypercalcemia, parotid and salivary glands, heart, liver, 
spleen and bone marrow. HLA-DRB1 alleles were determined for all individuals, and 
comparisons were made between different subgroups.  
 
4.5.1 The role of single human leukocyte antigen alleles  
We found that the risk for extra-thoracic engagement such as skin, ocular and 
peripheral lymph nodes was very low in LS patients and that the frequency was several 
times higher in non-LS patients. Moreover, there were significant differences between 
HLA-DRB1 alleles with respect to the risk for extra-pulmonary manifestations. Lowest 
was the risk for patients who carried the HLA-DRB1*03 allele. In contrast, the HLA-
DRB1*04 allele was a risk factor for extra-pulmonary manifestations. Compared to 
DRB1*03, the alleles DRB1*04, *07, *08 and *15 were associated with a significantly 
increased risk for extra-pulmonary manifestations. Moreover, HLA-DRB1*03 negative 
compared to DRB1*03 positive LS patients had a significantly increased risk for extra-
pulmonary manifestations. Correlation between disease progression and different HLA 
alleles has been seen also in other diseases than sarcoidosis; leprosy caused by 
Mycobacterium leprae is one example. In leprosy HLA alleles are believed to not only 
influence the susceptibility or resistance against disease, but also if the patient will 
develop a tuberculoid or lepromatous form of leprosy. The tuberculoid form of leprosy 
is associated with T helper 1 (cellular) immune response while the lepromatous form is 
related instead to a T helper 2 (humoral) response. How HLA molecules present 
peptides derived from M. leprae to T cells of the host is believed to be of importance 
for the immunologic reaction (331). Since there in sarcoidos are links between HLA-
type and disease expression, the differences in how the HLA-alleles present the 
sarcoidosis related antigen may influence the subsequent immune reaction. It has 
previously been shown that HLA-DRB1*03 in Scandinavian sarcoidosis patients is 
associated with LS and an expansion (>10%) of CD4+
 
T cells expressing a T cell 
receptor with a V gene segment, AV2S3, in bronchoalveolar lavage fluid (214). In 
conclusion, extra-pulmonary manifestations are common in non-LS sarcoidosis. 
Further, HLA-typing could be of clinical value for identification of patients with an 
increased risk for extra-pulmonary manifestations. 
 
 
4.5.2 Combinations of human leukocyte antigens 
We found that the risk for extra-pulmonary manifestation not only depended on the 
single HLA-DRB1 alleles, but also on how the alleles were combined. Patients with the 
combination HLA-DRB1*01/*03 had a relatively low risk of about 7% for extra-
pulmonary manifestations compared to the general risk for extra-pulmonary 
manifestations in patients who were either HLA-DRB1*01 or HLA-DRB1*03 positive 
where the risk was close to 20% in both cases. The risk was even lower in HLA-
DRB1*01/*03 positive patients who also had LS. A similar, but inverse phenomena is 
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seen in patients with type 1 diabetes where the HLA-DRB1 alleles *03 and *04 
separately are associated with an increased risk, but were the risk is highest for those 
who carry both the alleles. The presented theory in type 1 diabetes is not that there is a 
primarily link to the HLA-DRB1 alleles, but instead to the combinations of the strongly 
associated HLA-DQB1 and HLA-DQA1 alleles (316). The role of linkage 
disequilibrium, defined as the tendency for genetic variants located close to each other 
on the same chromosome to be associated within a population more often than if they 
were unlinked, have been discussed also in sarcoidosis. Since there is a strong linkage 
disequilibrium within the HLA-region there are difficulties to determine which gene/s 
represent the primary association, and whether non-HLA genes located in the region 
have any role for the risk of developing disease as well as for disease progression (224). 
As a summary, not only single HLA-DRB1 alleles influence the risk for extra-thoracic 
manifestations, but also combinations of certain alleles are of importance. 
 
 
4.5.3 Human leukocyte antigen DRB1*04/*15 a risk factor 
We found that HLA-DRB1*04 positive patients in general had a high risk for extra-
thoracic engagements, and  among the five most common HLA-DRB1 allele pairs the 
risk was highest for those patients who had the combination HLA-DRB1*04 /*15, 
where 50% had some form of extra-thoracic engagement. This shows that HLA-typing 
of sarcoidosis patients could be of clinical value for the identification of high risk 
patients and where especially the combination HLA-DRB1*04/*15 calls for an 
increased awareness and a more intensive follow-up. 
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5 CONCLUDING REMARKS 
 
 There was a correlation between HLA-DRB1*04 and symptoms associated 
with HS, which consists in its complete form of uveitis, parotid and/or salivary 
gland enlargement and cranial nerve palsy.  
 
 There was a prolonged disease course in sarcoidosis patients with ocular 
engagement. 
 
  The CD4/CD8-ratio in LNs of sarcoidosis patients seem to be of less diagnostic 
value, compared to BALF where a level >3.5 is used to strengthen the 
diagnosis. 
 
 In patients who harbored an expansion of AV2S3+ T cells, there was an inverse 
relation between the frequency of BALF AV2S3+ T cells and the fraction of 
BALF T cells expressing FOXP3. This indicates that patients with an expansion 
of AV2S3+ T cells more efficiently eliminate a presumed sarcoidosis-specific 
antigen and there is therefore a less need of FOXP3 expressing T cells (Tregs). 
 
 A pathologic ECG was found to be a risk marker for CS. With respect to our 
findings we therefore recommend that all sarcoidosis patients with an abnormal 
ECG should be further investigated for CS.  
 
 Male gender, advanced radiographic stages, non-LS and HLA-DRB1*15 were 
additional risk factors for CS.  
 
 The absence of HLA-DRB1*03 in LS patients was a risk factor for extra-
pulmonary manifestations (erythema nodosum and ankle arthritis excluded). 
Furthermore, HLA-DRB1*04 was in all sarcoidosis patients a risk factor for 
extra-pulmonary manifestations. 
 
 Not only single HLA-DRB1 alleles influenced the clinical picture seen in 
sarcoidosis patients, but also the allele combinations. Among the five most 
common HLA-DRB1 allele pairs in sarcoidosis patients, the highest risk for 
extra-pulmonary manifestations was seen in those with the combination HLA-
DRB1*04/*15. 
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6 FUTURE PERSPECTIVES 
 
 It would be of interest to investigate if HLA-DRB1*04 positive patients with 
uveitis express autoantibodies that are not found in HLA-DRB1*04 positive 
patients without ocular engagement. 
 
 Functional analyses could give us information about the regulatory capacity of 
FOXP3+ cells in BALF versus LN. 
 
 In sarcoidosis and as well as in other diseases such as rheumatoid arthritis, 
which also sometimes goes with pulmonary infiltrates, it has been discussed if 
there is an air-borne antigen that act as a triggering factor. One way to further 
investigate this theory could be to compare BALF from patients with 
sarcoidosis with findings from BALF of patients with other systemic diseases 
that also goes with pulmonary involvement. 
 
 Since a pathologic ECG seems to be a risk factor for cardiac involvement, it 
would be of interest to do a prospective study of ECG findings and the risk for 
cardiac sarcoidosis. 
 
 Not all patients with cardiac engagement develop arrhythmias and by 
comparing findings on CMR with findings from for example 24-hour 
ambulatory ECG, it may in the future be possible from CMR images to predict 
patients with a high risk for life-threatening arrhythmias. 
 
 AV2S3+ T cells are known to accumulate in BALF of HLA-DRB1*03 positive 
patients with active disease. Since patients with the HLA-DRB1*01/*03 
combination have a low risk for extra-pulmonary manifestations in comparison 
to patients with HLA-DRB1*03/*04, there might be differences also in the 
expression of BALF AV2S3 + T cells. 
 
 Sarcoidosis patients are often non-smokers and it may therefore be of interest to 
compare smokers with non-smokers who have sarcoidosis, to see if the disease 
progression differs between the two groups. 
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